Celebrating a Milestone in Alzheimer's Treatment

Profound Research extends our heartfelt congratulations to our sponsor partner, Eli Lilly, on the recent approval of Kinsunla™ by the Food and Drug Administration (FDA). This groundbreaking development marks a significant step forward in the battle against Alzheimer's disease, providing new hope to individuals and their families affected by this debilitating condition. 

To learn more about Kinsunla™, read the full release at Eli Lilly. 

Kinsunla™, now the second drug on the U.S. market aimed at slowing the progression of early-stage Alzheimer's, has demonstrated remarkable efficacy. According to Eli Lilly, the drug slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study. Furthermore, it reduced participants' risk of progressing to the next clinical stage of the disease by up to 39%. These promising results underscore the potential of Kinsunla™ to transform the landscape of Alzheimer's treatment. 

Profound Research at Neurology Center of Southern California (NCSC), under the leadership of Principal Investigator, Benjamin Frishberg, MD, is proud to serve as a site for the TRAILBLAZER program. Dr. Gregory Sahagian, CEO of NCSC and Chief Scientific Officer for Profound Research, emphasized the significance of this achievement, stating, "This is why we do clinical research. This is an advancement over previously approved therapies and a step forward in our fight to overcome Alzheimer’s Disease. Our patients have been enrolled in the study and were provided the opportunity for early access to a disease modifying therapy." 

April Tenorio, CCRC, Clinical Research Site Manager for Profound Research at NCSC, sharing her appreciation, stating: "As Kisunla™ steps into the market, the lasting impact of our site stands strong, showcasing the importance of teamwork, determination, and advancements in science. It serves as a reminder that behind every clinical research setting, there exists the opportunity to make a difference in people’s lives and shape the course of medical advancements. It has been a remarkable journey that we are all proud to be a part of!" 

This most recent achievement aligns with Profound Research's mission of contributing to continued innovation in medicine while improving health outcomes. Our involvement in the development and approval of Kinsunla™ highlights our commitment to progress and our dedication to supporting advancements that enhance the quality of life for patients.  

Once again, we commend Eli Lilly on this momentous development. With this promising new treatment, clinical research is paving the way for a brighter future for patients with Alzheimer's, bringing hope and potential benefits to those affected by this challenging disease.